The short answer
The current deferiprone label advises avoiding silymarin, a milk-thistle extract, because it may interfere with drug metabolism. Discuss the exact product with your specialist; a four-hour mineral-spacing rule does not resolve this separate concern.
What this answer covers
Oral deferiprone with silymarin-containing Silybum marianum products. Extract mixtures, isolated constituents and whole-plant products are not dose-equivalent.
- Supplement or preparation
- Silybum marianum
- Medication ingredient
- deferiprone
Check the exact oral medicine
This applies to oral deferiprone tablets such as FERRIPROX. Two different 1000 mg formulations use different twice-daily or three-times-daily schedules. Confirm your tablet and prescription; do not interchange regimens while fitting in supplements.
This is a metabolism precaution
Deferiprone is mainly glucuronidated by UGT1A6. The label names silymarin among inhibitors to avoid. Laboratory work supports the importance of this pathway, but does not itself show how much a particular milk-thistle preparation raises drug levels in a person.
Human co-use findings are more limited
An 80-child thalassemia study compared oral deferiprone plus silymarin with deferiprone plus placebo for nine months. Iron markers improved more with silymarin, without significant between-group differences in reported kidney or liver laboratory tests. It did not measure deferiprone concentrations or establish comprehensive safety, so it does not remove the current avoidance precaution.
Review the extract before use
Bring the brand, ingredients and silymarin content to the treating specialist. Do not use a claimed liver-protection benefit to justify starting it yourself. The four-hour instruction concerns mineral binding, not this enzyme issue. Continue prescribed blood-count and liver monitoring and do not alter deferiprone to compensate for a supplement.
Evidence and practical considerations
Side effects & toxicity
The exact label supports silymarin avoidance through a potential UGT1A6 metabolic interaction, while clinical co-use evidence does not demonstrate increased deferiprone concentrations or uniform toxicity.
- Exact scope
- Oral deferiprone with silymarin-containing Silybum marianum products. Extract mixtures, isolated constituents and whole-plant products are not dose-equivalent. with RxNorm11645 IN deferiprone. Exact oral FERRIPROX molecule; distinct twice-daily and three-times-daily1000 mg tablets have different regimens and are not interchangeable schedules.
- Medication form and route
- Oral
What remains uncertain
- Named current-label precaution, not a measured exact botanical dose-response or toxicity incidence. Original co-use trial abstract lacks detailed standardization, drug levels and comprehensive adverse-event data; favorable laboratory findings retained.
Factors that may matter: Exact oral release formulation; Mineral salt and combination ingredients; Dosing order and meals; Treatment indication.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed the specified oral formulation.
At least four-hour interval from polyvalent-cation medicines/supplements. Avoid UGT1A6 inhibitors including silymarin; monitor zinc and supplement if deficient.
How this applies: RxNorm11645 IN deferiprone. Exact oral FERRIPROX molecule; distinct twice-daily and three-times-daily 1000 mg tablets have different regimens and are not interchangeable schedules.
Potential binding and in-vitro metabolism evidence are not measured human exposure changes for every mineral/botanical product. Tablet regimen differences retained.
Source 2: Original medication-use guidance
medlineplus.gov · Source check Sep 10, 2026
Population: Users of oral deferiprone.
Four hours before or after listed antacids/multivitamins/iron/zinc. Discuss milk thistle separately; mineral timing does not resolve enzyme interaction.
How this applies: RxNorm11645 IN deferiprone. Exact oral FERRIPROX molecule; distinct twice-daily and three-times-daily 1000 mg tablets have different regimens and are not interchangeable schedules.
Practical guidance, not a trial proving every listed interval restores exposure. Direction and formulation matter.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 80 Egyptian children with beta-thalassemia major and iron overload, two groups of 40.
Ferritin and iron were lower with silymarin; no significant between-group differences in reported kidney/liver laboratory results.
How this applies: Only stated preparation, route and endpoint; clinical outcome and PK are distinct.
Abstract-only; no deferiprone concentrations, detailed botanical standardization or comprehensive toxicity assessment. Publisher403; does not establish universal safety or overturn current label avoidance.
Source 4: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Human tissue microsomes and recombinant UGT enzymes.
UGT1A6 predominantly glucuronidated deferiprone; variants differed in laboratory activity.
How this applies: Only stated preparation, route and endpoint; clinical outcome and PK are distinct.
Abstract-only laboratory system, no botanical co-use or measured human increase in drug exposure.
Source 5: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
deferiprone is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 1b892d89cc507793
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.